Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
luding full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/MACK
Sangamo BioSciences, Inc. Research Report
On August 26, 2013, Sangamo BioSciences, Inc. (Sangamo) announced that it has signed a definitive agreement to acquire Ceregene, Inc. (Ceregene), a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies.The Company informed that in accordance with the terms of the agreement, Sangamo will issue to the stockholders of Ceregene 100,000 shares of Sangamo's common stock, representing less than 0.2% of Sangamo's total shares outstanding. Further, the Company has agreed to make contingent earn-out payments to the stockholders of Ceregene based upon revenues generated from license or sales transaction of certain existing products of Ceregene. Sangamo expects the acquisition to close in September 2013, and does not expect it to have any impact on the Company's financial guidance for full-year 2013 operating expenses or year-end cash balance. The Full Research Report on Sangamo BioSciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/SGMO]
PDL BioPharma, Inc. Research Report
On September 9, 2013, PDL BioPharma, Inc. (PDL) announced revenue guidance for Q3 2013. The Company expects revenues of approximately $97 million, as compared with revenues of $85 million reported in Q3 2012, representing an increase of 14.1% YoY. The Company informed that its revenue guidance is driven by increased Q2 2013 sales for Avastin, Herceptin, Lucentis, Xolair, Kadcyla, Perjeta, and Actemra, for which PDL receives royalties in Q3 20Page: 1 2 3 4 5 Related biology technology :1
. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 20112
. Puma Biotechnology Announces Completion of Private Placement3
. Animal Biotechnology - Technologies, Markets and Companies4
. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug5
. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem6
. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-327657
. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium8
. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech9
. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 1210
. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 201211
. Selexis SA to Present at Biotech Showcase 2012
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... 2014 3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ... Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... previously reported, communicated in late 2007 ... ... Biotech Products, L.P.,today modified prescribing information for PROCRIT(R) (Epoetin alfa),following guidance from ... within the erythropoiesis-stimulating agent,(ESA) class., Modifications to the label were based ...
... by the Environmental Protection Agency (EPA) to fine California ... nano-pesticides is being applauded by David Rejeski, the director ... should receive a big pat on the back for ... federal pesticide law that has been on the books ...
... FRANKLIN LAKES, N.J., March 7 BD (Becton,Dickinson and Company) ... that it would present at the following investor healthcare,conferences:, ... 13, 2008 8:45 a.m. Greenwich Mean Time (4:45 a.m. ... Company 28th Annual Healthcare Conference March 20, 2008 ...Cached Biology Technology:Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 5Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 6Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 7
(Date:7/9/2014)... climate change shifts the geographic ranges in which animals ... has on their parasites. Does an increased range for ... well? , Not necessarily, says a team of UC ... Kuris. In a study published in the Journal ... for some species, the opposite may happen: Hosts may ...
(Date:7/9/2014)... NY, July 9, 2014Biofuels derived from the oils produced ... fossil fuels. To achieve this goal, optimization of cost ... open pond systems, is needed. Sapphire Energy has developed ... open pond algae cultivation systems, described in Industrial ... Inc., publishers. The article is available on the ...
(Date:7/9/2014)... URBANA, Ill. With over 100 diseases that can ... the top of the most wanted list? University of ... reason that more research is needed on the fungus ... associated with cool, damp growing conditions but Macrophomina ... hot and dry drought conditions. , "As the climate ... Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4Controlling contamination in open algae ponds for biofuels 2Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... An entire pressurized perfusion system ... in physiology, biophysics, electrochemistry, or general ... as little as 100 microliters of ... eight solutions in milliseconds from a ...
Request Info...Biology Products: